Abstract： Objective： To investigate the potential mechanism of Xuanbi Decoction in treating chikungunya arthralgia using network pharmacology and molecular docking technology. Methods： Active ingredients and target genes of Xuanbi Decoction were screened using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform （TCMSP） and the Encyclopedia of Traditional Chinese Medicine （ETCM） database. Disease-related targets for chikungunya arthralgia were retrieved from GeneCards， OMIM， and DisGeNET databases. The STRING database was used to construct a protein-protein interaction （PPI） network of intersecting targets to predict core targets. The Metascape database was employed for Gene Ontology （GO） biological function annotation and Kyoto Encyclopedia of Genes and Genomes （KEGG） pathway enrichment analysis of intersecting targets. Finally， molecular docking validation of active ingredients and core targets was performed using AutoDock Tools. Results： Xuanbi Decoction contained 74 main components and 263 potential target genes. There were 681 disease-related targets for chikungunya arthralgia， with 30 intersecting targets identified. The potential active components of Xuanbi Decoction for treating chikungunya arthralgia mainly included quercetin，wogonin，luteolin，kaempferol，baicalein，and stigmasterol. Core targets included MAPK14， RELA， PTGS2， TNF， and IL-6. The GO analysis results comprised 488 biological processes，8 cellular components，and 29 molecular functions. KEGG pathway enrichment was primarily observed in the AGE-RAGE signaling pathway，IL-17 signaling pathway，TNF signaling pathway，and others. Molecular docking demonstrated strong binding activity between the main active components and core targets. Conclusion： The mechanism of Xuanbi Decoction in treating chikungunya arthralgia may involve multiple components， such as quercetin， wogonin， and luteolin， acting on multiple targets including MAPK14， RELA， and PTGS2， and regulating multiple pathways such as the AGE-RAGE，IL-17，and TNF signaling pathways.